Streptomyces Patents (Class 435/252.35)
-
Publication number: 20130109069Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO. The invention additionally provides methods of using such microbial organisms to produce BDO.Type: ApplicationFiled: April 17, 2012Publication date: May 2, 2013Applicant: GENOMATICA, INC.Inventors: Mark J. Burk, Anthony P. Burgard, Robin E. Osterhout, Jun Sun
-
Publication number: 20130111613Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: September 17, 2012Publication date: May 2, 2013Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Publication number: 20130109064Abstract: The invention provides non-naturally occurring microbial organisms containing 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol pathways comprising at least one exogenous nucleic acid encoding a butadiene pathway enzyme expressed in a sufficient amount to produce 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol. The invention additionally provides methods of using such microbial organisms to produce 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol, by culturing a non-naturally occurring microbial organism containing 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol pathways as described herein under conditions and for a sufficient period of time to produce 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol, crotyl alcohol or 3-buten-1-ol.Type: ApplicationFiled: August 17, 2012Publication date: May 2, 2013Inventors: Robin E. Osterhout, Anthony P. Burgard, Mark J. Burk
-
Publication number: 20130102667Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: ApplicationFiled: October 22, 2012Publication date: April 25, 2013Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventor: E.I. Du Pont De Nemours And Company
-
Publication number: 20130102669Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: ApplicationFiled: October 22, 2012Publication date: April 25, 2013Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventor: E. I. Du Pont De Nemours And Company
-
Publication number: 20130102668Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: ApplicationFiled: October 22, 2012Publication date: April 25, 2013Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventor: E. I. Du Pont De Nemours And Company
-
Publication number: 20130102035Abstract: The present invention relates to combinatorial variants of a parent glucoamylase that have altered properties for reducing the synthesis of condensation products during hydrolysis of starch. Accordingly the variants of a parent glucoamylase are suitable such as for use within brewing and glucose syrup production. Also disclosed are DNA constructs encoding the variants and methods of producing the glucoamylase variants in host cells.Type: ApplicationFiled: June 30, 2011Publication date: April 25, 2013Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Peter Edvard Degn, Richard R. Bott, Casper Willem Vroemen, Martijn Silvan Scheffers, Wolfgang Aehle, Elin Petersen
-
Publication number: 20130102664Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: ApplicationFiled: October 22, 2012Publication date: April 25, 2013Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventor: E. I. du Pont de Nemours and Company
-
Publication number: 20130102666Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: ApplicationFiled: October 22, 2012Publication date: April 25, 2013Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventor: E. I. Du Pont De Nemours And Company
-
Publication number: 20130102671Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: ApplicationFiled: October 22, 2012Publication date: April 25, 2013Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventor: E. I. Du Pont De Nemours And Company
-
Publication number: 20130102672Abstract: An acetyl xylan esterase variant having perhydrolytic activity is provided for producing peroxycarboxylic acids from carboxylic acid esters and a source of peroxygen. More specifically, a Thermotoga maritima acetyl xylan esterase gene was modified using error-prone PCR and site-directed mutagenesis to create an enzyme catalyst characterized by an increase in specific activity. The variant acetyl xylan esterase may be used to produce peroxycarboxylic acids suitable for use in a variety of applications such as cleaning, disinfecting, sanitizing, bleaching, wood pulp processing, and paper pulp processing applications.Type: ApplicationFiled: October 22, 2012Publication date: April 25, 2013Applicant: E. I. DU PONT DE NEMOURS AND COMPANYInventor: E.I. Du Pont De Nemours And Company
-
Publication number: 20130101590Abstract: The invention provides novel BTNL9 proteins, including multimers, fragments, and variants of a human BTNL9 protein. In addition, antibodies that can bind to BTNL9 proteins and nucleic acids encoding BTNL9 proteins are provided. Uses for BTNL9 proteins, and agonists or antagonists thereof, are described.Type: ApplicationFiled: April 8, 2011Publication date: April 25, 2013Inventors: Heather A. Arnett, Sabine S. Escobar, Ryan M. Swanson, Joanne L. Viney
-
Publication number: 20130096078Abstract: Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces<i/> species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.Type: ApplicationFiled: October 14, 2010Publication date: April 18, 2013Applicant: EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATIONInventors: Yeo Joon Yoon, Sung Ryeol Park, Je Won Park, Jae Kyung Sohng
-
Publication number: 20130095540Abstract: The invention provides a non-naturally occurring microbial organism having an adipate, 6-aminocaproic acid or caprolactam pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective adipate, 6-aminocaproic acid or caprolactam pathway. The invention additionally provides a method for producing adipate, 6-aminocaproic acid or caprolactam. The method can include culturing an adipate, 6-aminocaproic acid or caprolactam producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an adipate, 6-aminocaproic acid or caprolactam pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce adipate, 6-aminocaproic acid or caprolactam.Type: ApplicationFiled: June 15, 2012Publication date: April 18, 2013Applicant: Genomatica, Inc.Inventors: Anthony P. BURGARD, Priti Pharkya, Robin E. Osterhout
-
Publication number: 20130095533Abstract: The present invention is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS) derived drug and analogs thereof. The invention also discloses polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS derived drug.Type: ApplicationFiled: April 15, 2011Publication date: April 18, 2013Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, CLORADO STATE UNIVERSITY RESEARCH FOUNDATION, ALLEGHENY-SINGER RESEARCH INSTITUTEInventors: David H. Sherman, Garth D. Ehrlich, Benjamin Janto, Robert M. Williams, Christopher M. Rath
-
Publication number: 20130089898Abstract: The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3?-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients.Type: ApplicationFiled: June 16, 2011Publication date: April 11, 2013Applicant: CODEXIS, INC.Inventors: Fabien Cabirol, Anupam Gohel, Seong Ho Oh, Derek Smith, Brian Wong, James Lalonde
-
Publication number: 20130089554Abstract: This disclosure provides immunoglobulin binding molecules that specifically bind to human macrophage stimulating receptor (MST1 R, also referred to herein as recepteur d'origine Nantaise or RON), including antibodies and monospecific and multispecific single chain binding proteins having one or more other domains, such as one or more antibody constant region domains. Also provided are therapeutic applications of such binding proteins, such as for the treatment of cancer and inflammatory disorders.Type: ApplicationFiled: December 29, 2010Publication date: April 11, 2013Applicant: Emergent Product Development Seattle, LLCInventors: John W. Blankenship, Philip Tan, Sateesh Kumar Natarajan, Paul A. Algate, Ruth A. Chenault
-
Publication number: 20130089906Abstract: The invention provides for methods for the production of mevalonate, isoprene, isoprenoid precursor molecules, and/or isoprenoids in cells via the heterologous expression of phosphoketolase enzymes.Type: ApplicationFiled: October 5, 2012Publication date: April 11, 2013Inventors: Zachary Q. BECK, Andrew C. ELIOT, Caroline M. PERES, Dmitrii V. VAVILINE
-
Publication number: 20130090290Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.Type: ApplicationFiled: March 21, 2011Publication date: April 11, 2013Applicant: LIFENET HEALTHInventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James A. Clagett
-
Publication number: 20130089897Abstract: The present invention relates to isolated polypeptides having isoamylase activity derived from Dyella japonica and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. The invention also relates to the use of said polypeptide having isoamylase activity for producing glucose syrup, fructose syrup, maltose syrup or maltitol.Type: ApplicationFiled: December 10, 2012Publication date: April 11, 2013Applicant: NOVOZYMES A/SInventor: NOVOZYMES A/S
-
Patent number: 8404467Abstract: The object of the present invention is to provide processes for producing an antiaging agent, a vulcanization accelerator and a modified natural rubber, which are environmentally friendly and allow to make provision against a decrease of petroleum resources in the future. According to the present invention, glucose is used as carbon neutral resources and is converted into aniline or an aniline derivative by a microorganism. An antiaging agent, a vulcanization accelerator or a modified natural rubber is produced from thus obtained aniline or aniline derivative.Type: GrantFiled: March 28, 2008Date of Patent: March 26, 2013Assignee: Sumitomo Rubber Industries, Ltd.Inventor: Keitaro Fujikura
-
Publication number: 20130071886Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO) pathway comprising at least one exogenous nucleic acid encoding a BDO pathway enzyme expressed in a sufficient amount to produce BDO. The invention additionally provides methods of using such microbial organisms to produce BDO.Type: ApplicationFiled: August 3, 2012Publication date: March 21, 2013Applicant: GENOMATICA, INC.Inventors: Mark J. Burk, Anthony P. Burgard, Robin E. Osterhout, Jun Sun
-
Publication number: 20130071883Abstract: The invention provides a non-naturally occurring microbial organism having an acetyl-CoA pathway and the capability of utilizing syngas or syngas and methanol. In one embodiment, the invention provides a non-naturally occurring microorganism, comprising one or more exogenous proteins conferring to the microorganism a pathway to convert CO, CO2 and/or H2 to acetyl-coenzyme A (acetyl-CoA), methyl tetrahydrofolate (methyl-THF) or other desired products, wherein the microorganism lacks the ability to convert CO or CO2 and H2 to acetyl-CoA or methyl-THF in the absence of the one or more exogenous proteins.Type: ApplicationFiled: September 13, 2012Publication date: March 21, 2013Applicant: GENOMATICA, INC.Inventors: Mark J. BURK, Christophe H. SCHILLING, Anthony P. BURGARD, John D. TRAWICK
-
Publication number: 20130065284Abstract: A modified microorganism for high efficient production of lactic acid, an expression vector for constructing the modified microorganism, and a method of producing a lactic acid using the same are disclosed. The modified microorganism may produce lactic acid at a high level under acid conditions.Type: ApplicationFiled: June 22, 2012Publication date: March 14, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Soon Chun CHUNG, Hyun Min KOO, Jae Young KIM, Ji Eun KIM, Jin Woo KIM, Young kyoung PARK, So Young LEE, Hwa Young CHO, Dae Huck KWON, Jae Chan PARK
-
Publication number: 20130065279Abstract: The invention provides a non-naturally occurring microbial organism having a methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in a methacrylic acid pathway. The invention additionally provides a method for producing methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate. The method can include culturing methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding a methacrylic acid pathway enzyme in a sufficient amount to produce methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate, under conditions and for a sufficient period of time to produce methacrylic acid, methacrylate ester, 3-hydroxyisobutyrate and/or 2-hydroxyisobutyrate.Type: ApplicationFiled: March 30, 2012Publication date: March 14, 2013Applicant: Genomatica, Inc.Inventors: Mark J. BURK, Anthony P. Burgard, Robin E. Osterhout, Jun Sun, Priti Pharkya
-
Publication number: 20130067608Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: August 16, 2012Publication date: March 14, 2013Applicant: CELERA CORPORATIONInventors: Bruno DOMON, Aiqun LI, Tao HE, Ian MCCAFFERY
-
Publication number: 20130059034Abstract: The present invention relates to polypeptides, specifically polypeptides having transgalactosylating activity and nucleic acids encoding these, and their uses in e.g. dairy product.Type: ApplicationFiled: March 29, 2011Publication date: March 7, 2013Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Morten Krog Larsen, Charlotte Horsmans Poulsen
-
Publication number: 20130058927Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: ApplicationFiled: October 31, 2012Publication date: March 7, 2013Applicant: GENENTECH, INC.Inventor: GENENTECH, INC.
-
Publication number: 20130052694Abstract: Provided are isolated cellobiohydrolases comprising a modified Glycoside Hydrolase (GH) Family 7 catalytic domain, a GH Family 7 catalytic domain and a modified Family 1 carbohydrate binding module (CBM), or both a modified Family 7 catalytic domain and a modified Family 1 CBM. Such isolated cellobiohydrolases exhibit from 45% to about 99.9% amino acid sequence identity to amino acids 1-436 of SEQ ID NO: 1 or to amino acids 1-438 of SEQ ID NO: 2 and improved activity on process substrates. Also provided are genetic constructs and genetically modified microbes for expressing the isolated cellobiohydrolases, a process for producing the isolated cellobiohydrolases, cellulase enzyme mixtures comprising the isolated cellobiohydrolase and a process for hydrolysing a cellulosic substrate with such cellulase enzyme mixtures.Type: ApplicationFiled: August 24, 2012Publication date: February 28, 2013Applicant: Iogen Energy CorporationInventors: Jacqueline Montalibet, Loreta Gudynaite-Savitch, Christopher Hill, Christopher D. Hindle, James A. Lavigne, Nabil Masri, Fuad Tahna, John J. Tomashek
-
Host Cells and Methods for Producing 1-Deoxyxylulose 5-phosphate (DXP) and/or a DXP Derived Compound
Publication number: 20130052692Abstract: The present invention provides for a genetically modified host cell capable of producing 1-deoxyxylulose 5-phosphate or 1-deoxy-D-xylulose 5-phosphate (DXP) (12), and optionally one or more DXP derived compounds, comprising: (a) a mutant RibB, or functional variant thereof, capable of catalyzing xylulose 5-phosphate and/or ribulose 5-phosphate to DXP, or (b) a YajO, or functional variant thereof, and a XylB, or functional variant thereof.Type: ApplicationFiled: August 16, 2012Publication date: February 28, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: James Kirby, Jeffrey L. Fortman, Minobu Nishimoto, Jay D. Keasling -
Publication number: 20130052684Abstract: The invention provides a promoter derived from a genome of an actinomycete, Streptomyces species, and can specifically induce expression of a transgene in an actinomycete, Streptomyces species, in and after a logarithmic growth phase, and an actinomycete host having a high secondary metabolite production ability and a high precursor supply ability in and after the logarithmic growth phase, and a method for producing useful substances in which the promoter and the actinomycete host are combined.Type: ApplicationFiled: March 2, 2011Publication date: February 28, 2013Inventors: Kazuya Yamanaka, Yoshimitsu Hamano, Tomohiro Yoshimura
-
Publication number: 20130052686Abstract: The present invention relates to isolated polypeptides having alpha-L-arabinofuranosidase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: October 26, 2012Publication date: February 28, 2013Applicant: NOVOZYMES A/SInventors: Michelle Maranta, Kimberly Brown, James Langston
-
Publication number: 20130052179Abstract: The present invention relates to an arginine deiminase mutant with partial lysine-deficient and preparation and application thereof. The arginine deiminase mutant of the present invention has enzymatic activity of degrading arginine into citruline; compared with the arginine deiminase with the amino acid sequence of SEQ ID NO: 1, the amino acid sequence comprises one or more of K9N, T, K59Q, K66R, A, K93E, A, Q, K111R, A, K119Q, L, M, K121Q, I, K122E, L, K126E, S, R, K178I, E, D, K196I, R, K209G, T, D, K243E, V, R, K249D, Q, K263N, Q, K279Y, T, K293R, H, E, K325V, I, K380T, R, E, and K406E, D, S substitutions. Compared with PEG modified natural derived arginine deiminase, the PEG modified arginine deiminase mutant of the present invention retain better bioactivity; and because the quantity of lysine in arginine deiminase is reduced, the PEG modified products are more uniform and can be applied to clinical treatment of hepatoma, melanoma and the like.Type: ApplicationFiled: August 22, 2011Publication date: February 28, 2013Inventors: Yanshan HUANG, Jiwan Qiu, Xiaoyu Fu, Min Fan, Yujiao Wang, Yefei Wang
-
Publication number: 20130052699Abstract: The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.Type: ApplicationFiled: May 4, 2011Publication date: February 28, 2013Applicant: CODEXIS, INC.Inventors: Michael Crowe, Oscar Alvizo, Behnaz Behrouzian, Yong Koy Bong, Steven J. Collier, Anupam Gohel, Jagadeesh Mavinahalli, Naga Modukuru, Emily Mundorff, Derek Smith, Shiwei Song, Wan Lin Yeo
-
Publication number: 20130052679Abstract: A method for analyzing L-threonine contained in an specimen, which includes the steps of mixing a sample containing the specimen with an L-threonine dehydrogenase derived from Cupriavidus necator and a coenzyme NAD+ and analyzing the amount of NADH or 2-amino-3-oxobutyric acid after a predetermined period; an L-threonine dehydrogenase derived from Cupriavidus necator, which is a novel L-threonine dehydrogenase (TDH; EC 1.1.1.103) and can be utilized in the above-mentioned analysis method; a method for preparing a gene or the like to be used in the preparation of the enzyme, or a method for preparing the enzyme; an L-threonine analysis kit which includes (A) the L-threonine dehydrogenase and (B) a coenzyme NAD+; an enzyme preparation for use in the analysis of L-threonine, which includes the L-threonine dehydrogenase contained in a buffer solution; and an enzyme sensor utilizing the L-threonine dehydrogenase.Type: ApplicationFiled: September 4, 2012Publication date: February 28, 2013Inventors: Yasuhisa Asano, Techawaree Ueatrongchit
-
Publication number: 20130045219Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.Type: ApplicationFiled: October 22, 2012Publication date: February 21, 2013Applicants: BIOGEN IDEC MA INC., UCB PHARMA S.A.Inventors: UCB Pharma S.A., Biogen Idec MA Inc.
-
Publication number: 20130040346Abstract: The present invention relates to variants of a parent cellobiohydrolase. The present invention also relates to polynucleotides encoding the cellobiohydrolase variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the cellobiohydrolase variants.Type: ApplicationFiled: March 29, 2011Publication date: February 14, 2013Applicant: NOVOZYMES, INC.Inventor: Mark Wogulis
-
Publication number: 20130034894Abstract: A highly active allene oxide synthase that can be used in the production of a plant growth regulating agent (KODA) is provided.Type: ApplicationFiled: March 30, 2011Publication date: February 7, 2013Inventors: Mineyuki Yokoyama, Sari Kamichi, Kazuteru Takagi
-
Publication number: 20130034558Abstract: Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.Type: ApplicationFiled: January 26, 2011Publication date: February 7, 2013Applicant: SHANGHAI CANCER INSTITUTEInventors: Zonghai Li, Hai Wang, Min Zhou, Xiaorong Pan, Jianren Gu, Shengli Yang
-
Publication number: 20130035472Abstract: The invention is directed to a method of preparing a nucleic acid sequence with a modified splice site usage profile, which employs the use of a nucleic acid sequence comprising a cryptic splice donor site. The invention also provides a method of producing an alternate form of an RNA molecule encoded by a nucleic acid sequence, which nucleic acid sequence comprises a cryptic splice donor site, a heterologous nucleic acid sequence, and a splice acceptor site.Type: ApplicationFiled: March 15, 2011Publication date: February 7, 2013Applicant: ANAPTYSBIO, INC.Inventors: Robert Horlick, John Macomber, Andrew Cubitt, David King
-
Patent number: 8367393Abstract: The invention relates to an improved Saccharomyces strain displaying improved viability and growth during anaerobic fermentation of pentose carbon sources such as xylose and producing fermentation products such as ethanol.Type: GrantFiled: November 20, 2009Date of Patent: February 5, 2013Assignee: C5 Ligno Technologies Lund ABInventors: Bärbel Hahn-Hägerdal, Oskar Bengtsson, Maurizio Bettiga, Rosa Garcia Sanchez, David Rundquist, Marie-Francoise Gorwa-Grauslund
-
Publication number: 20130029381Abstract: The invention provides non-naturally occurring microbial organisms comprising a 1,4-butanediol (BDO), 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway comprising at least one exogenous nucleic acid encoding a BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine pathway enzyme expressed in a sufficient amount to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine and further optimized for expression of BDO. The invention additionally provides methods of using such microbial organisms to produce BDO, 4-hydroxybutyryl-CoA, 4-hydroxybutanal or putrescine.Type: ApplicationFiled: April 13, 2012Publication date: January 31, 2013Applicant: GENOMATICA, INC.Inventors: Robert Haselbeck, John D. Trawick, Wei Niu, Anthony P. Burgard
-
Publication number: 20130031676Abstract: The present invention relates to isolated polypeptides having glucoamylase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: April 11, 2011Publication date: January 31, 2013Applicant: Novozymes A/SInventors: Ming Li, Junxin Duan, Zheng Liu, Shiro Fukuyama, Keiichi Ayabe, Guillermo Coward-Kelly, Randall Deinhammer
-
Publication number: 20130023028Abstract: The invention relates to a method of preparing a variant of a parent polypeptide comprising: (a) providing an amino acid sequence of a parent polypeptide; (b) substituting at least one amino acid residue at a position in the sequence corresponding to any of positions: 41, 83, 129, 207 or 284 in SEQ ID No: 2; (c) selecting a variant with lipolytic activity, which compared to the parent polypeptide has improved stability, and has an amino acid sequence with at least 60% identity to the mature polypeptide of SEQ ID No: 2; and (d) recovering the variant.Type: ApplicationFiled: December 2, 2010Publication date: January 24, 2013Applicants: Novozymes South Asia Pvt. Ltd., Novozymes A/SInventors: Allan Svendsen, Sangeeta Naik, Saikia Rakhi, Aditya Basu, Pritish Paul, Santhosh Maypadum Vasu, Leonardo De Maria, Michael Skjot
-
Publication number: 20130024956Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicants: PFIZER INC., AMGEN FREMONT INC.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Publication number: 20130025005Abstract: The present invention relates to isolated polypeptides having lipase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: August 30, 2012Publication date: January 24, 2013Applicants: Novozymes A/S, Novozymes, Inc.Inventors: Debbie Yaver, Suzanne Otani, Janine Lin, Christopher Amolo, Kim Borch, Shamkant Anant Patkar, Michael Lamsa, Barbara Cherry
-
Publication number: 20130017209Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: John E. PARK, Cornelia DORNER-CIOSSEK, Stefan HOERER, Lothar KUSSMAUL, Martin LENTER, Katharina ZIMMERMANN, Gerald BESTE, Toon LAEREMANS, Pascal MERCHIERS, Jo VERCAMMEN
-
Publication number: 20130018174Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.Type: ApplicationFiled: December 24, 2010Publication date: January 17, 2013Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuya Wakabayashi, Eriko Ito
-
Patent number: 8354272Abstract: An expression cassette comprising: a) a bacterial promoter, pZn, containing a binding site for the Lactococcus lactis ZitR protein, which site comprises the following sequence: AAAAATAANGTNNNNNNNTTGACATTATTTTT, (SEQ?ID?NO:?1) in which TTGACA is the ?35 box of said promoter, and N represents A, C, G or T; b) a sequence encoding a polypeptide with at least 80% identity with the Lactococcus lactis ZitR protein, placed under the transcriptional control of said promoter; and wherein the polypeptide is obtained from Lactococcus; and c) at least one restriction site allowing the insertion of a nucleotide sequence of interest under the transcriptional control of said promoter, and wherein the expression cassette does not comprise any part of the sequence encoding the L. lactis ZitS protein.Type: GrantFiled: November 9, 2005Date of Patent: January 15, 2013Assignee: Institut National de la Recherche AgronomiqueInventors: Isabelle Poquet, Daniel Llull
-
Publication number: 20130011919Abstract: The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided.Type: ApplicationFiled: June 17, 2010Publication date: January 10, 2013Inventor: Alexey Ryazanov